# Alvotech (ALVO)

> Source: Nexqual · https://nexqual.com/ALVO · data as of 2026-10-23 16:21 UTC · cite as "Nexqual, Alvotech (ALVO), nexqual.com/ALVO" · informational, not investment advice.

**Price:** USD 4.64 (-3.24% today) · US market open, as of October 23, 2026 at 16:21 UTC; quotes may be delayed. Prev close 4.79 · day 4.63–4.78 · 52w 2.94–8.5 · market cap $1.65B · NGM

## Key facts
- 1 of 80 tracked superinvestors hold ALVO (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Total return with dividends: 1Y -43.1% vs S&P 500 +14.7%; 5Y -52.2% vs S&P 500 +77.5%.
- Next earnings: 2026-11-11, EPS estimate USD -0.05, revenue estimate $138M.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold ALVO. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Howard Marks | Oaktree Capital | 0.04% | $1.4M | Reduced -0.1% |

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-16 | Barclays | Upgrade | Underweight → Overweight | $4 → $8 |
| 2026-08-24 | B of A Securities | Initiated | Buy | $7 |
| 2026-08-14 | Evercore ISI Group | Initiated | Outperform |  |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2022-06-13) |
|---|---|---|
| Total return | -43.1% | -52.2% |
| S&P 500 (SPY) | +14.7% | +77.5% |
| Per year | -43.1% | -15.6% |
| Volatility (annualized) | 81.3% | 59.8% |
| Max drawdown | -64.3% (Oct 2025→Jun 2026) | -80.9% (Feb 2024→Jul 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.37 -1.93% · HCM (HUTCHMED (China) Limited) USD 14.32 +0.25% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.61 -3.36% · LQDA (Liquidia Corporation) USD 41 +3.29% · INDV (Indivior Pharmaceuticals, Inc.) USD 34.3 -2.92% · RGC (Regencell Bioscience Holdings L) USD 8.65 -11.82%

## More
Full page: https://nexqual.com/ALVO · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ALVO's own 20-F filed 2026-03-31 (https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/alvo-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Stada Arzneimittel | "Alvotech has entered into a number of license and supply agreements with STADA pursuant to which we granted STADA licenses on an exclusive or semi exclusive basis (depending on the market) to import, commercialize and ma…" |
| Supplier | The Nasdaq Stock Market | "As long as we rely on the foreign private issuer exemption to certain of Nasdaq's corporate governance standards, a majority of the directors on our board of directors are not required to be independent directors, our re…" |
| Partner | Fuji Pharma | "Our ability to continue to generate revenue and achieve sustainable profitability will continue to depend on our ability and that of our strategic collaboration partners, to successfully commercialize our first approved …" |
| Partner | Teva Pharmaceuticals International | "Our partners include Teva (U.S.), STADA (EU), Fuji Pharma Co., Ltd (Japan), JAMP Pharma (Canada), Advanz Pharma (EEA, U.K., Switzerland, Canada, Australia and New Zealand) and Dr. Reddy's (Global) among many others." |
| Partner | Laboratories | "Alvotech and our partner Dr. Reddy's Laboratories are involved in legal proceedings adverse to Amgen that may have an impact on our AVT 03 product in the United States." |
| Partner | Alvogen | "As of the date hereof, our two largest shareholders, Alvogen Lux Holdings S.à r.l. ("Alvogen") and Aztiq Pharma Partners SARL ("Aztiq"), own approximately 62.2% of our ordinary shares." |
| Partner | Kashiv Biosciences | "In 2023, we announced an agreement with Kashiv Biosciences LLC ("Kashiv") to in-license AVT23." |
| Partner | JAMP Pharma | "Our partners include Teva (U.S.), STADA (EU), Fuji Pharma Co., Ltd (Japan), JAMP Pharma (Canada), Advanz Pharma (EEA, U.K., Switzerland, Canada, Australia and New Zealand) and Dr. Reddy's (Global) among many others." |
| Competitor | AbbVie (ABBV) | "For example, in the market for AVT02, our biosimilar to Humira (adalimumab), we compete against AbbVie (the originator), Amgen, Boehringer Ingelheim GmbH, Biocon, Celltrion, Fresenius Kabi, Pfizer, Samsung Bioepis, Coher…" |
| Competitor | Pfizer (PFE) | "For example, in the market for AVT02, our biosimilar to Humira (adalimumab), we compete against AbbVie (the originator), Amgen, Boehringer Ingelheim GmbH, Biocon, Celltrion, Fresenius Kabi, Pfizer, Samsung Bioepis, Coher…" |
| Competitor | Johnson & Johnson (JNJ) | "In addition to Johnson & Johnson's (the originator's) reference product, we can face competition from other approved biosimilars for Stelara (ustekinumab) in the U.S. and EEA, including biosimilars from Intas, Amgen, Bio…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.05 | $0.02 | -362.7% | $138.1M | 2 |
| Next quarter (ends 2026-12-31) | $0.21 | $0.08 | +164.1% | $308.6M | 2 |
| Current fiscal year (ends 2026-12-31) | $-0.03 | $0.03 | -205.5% | $652.7M | 4 |
| Next fiscal year (ends 2027-12-31) | $0.23 | $0.23 | -2.0% | $785.9M | 5 |